New β-lactam-β-lactamase inhibitor combinations in clinical development (Q38076455)

28 August 2017

1 reference

title

New β-lactam-β-lactamase inhibitor combinations in clinical development (English)

1 reference

28 August 2017

David M Shlaes

1

1 reference

PubMed ID

23346860

28 August 2017

language of work or name

English

0 references

publication date

1 January 2013

1 reference

Annals of the New York Academy of Sciences

28 August 2017

1 reference

28 August 2017

1277

1 reference

28 August 2017

105-114

1 reference

In vivo comparison of CXA-101 (FR264205) with and without tazobactam versus piperacillin-tazobactam using human simulated exposures against phenotypically diverse gram-negative organisms

28 August 2017

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12010

Epidemiological expansion, structural studies, and clinical challenges of new β-lactamases from gram-negative bacteria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12010

Three decades of beta-lactamase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12010

Kinetic interactions of tazobactam with beta-lactamases from all major structural classes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12010

Diazabicyclooctanes (DBOs): a potent new class of non-β-lactam β-lactamase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12010

Inhibition of the SHV-1 beta-lactamase by sulfones: crystallographic observation of two reaction intermediates with tazobactam

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12010

In vitro activity of MK-7655, a novel β-lactamase inhibitor, in combination with imipenem against carbapenem-resistant Gram-negative bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12010

Mechanistic studies of the inactivation of TEM-1 and P99 by NXL104, a novel non-beta-lactam beta-lactamase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12010

Avibactam is a covalent, reversible, non-β-lactam β-lactamase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12010

Inhibition of the renal excretion of tazobactam by piperacillin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12010

Ceftazidime-resistant Klebsiella pneumoniae isolates recovered at the Cleveland Department of Veterans Affairs Medical Center

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12010

Class A beta-lactamases--enzyme-inhibitor interactions and resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12010

Carbapenemases: the versatile beta-lactamases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12010

In vitro activity of CXA-101 plus tazobactam (CXA-201) against CTX-M-14- and CTX-M-15-producing Escherichia coli and Klebsiella pneumoniae

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12010

Antimicrobial activity of CXA-101, a novel cephalosporin tested in combination with tazobactam against Enterobacteriaceae, Pseudomonas aeruginosa, and Bacteroides fragilis strains having various resistance phenotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12010

Activity of ceftaroline-avibactam tested against Gram-negative organism populations, including strains expressing one or more β-lactamases and methicillin-resistant Staphylococcus aureus carrying various staphylococcal cassette chromosome mec types

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12010

In vitro activity of ceftazidime combined with NXL104 versus Pseudomonas aeruginosa isolates obtained from patients in Canadian hospitals (CANWARD 2009 study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12010

Characterization of β-lactamase and porin mutants of Enterobacteriaceae selected with ceftaroline + avibactam (NXL104).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12010

Pharmacodynamics of β-lactamase inhibition by NXL104 in combination with ceftaroline: examining organisms with multiple types of β-lactamases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12010

In vitro activity of ceftaroline (PPI-0903M, T-91825) against bacteria with defined resistance mechanisms and phenotypes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12010

Activities of NXL104 combinations with ceftazidime and aztreonam against carbapenemase-Producing Enterobacteriaceae

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12010

21 January 2018

Identifiers

DOI

10.1111/NYAS.12010

1 reference

28 August 2017

1 reference

PubMed ID

23346860